Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/bacterial-chassis-transporter-engineering-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Bacterial Chassis Transporter EngineeringBacterial chassis transporter engineering patents: who holds the uptake and export claims
- 41.9% sits with five filers. The top 5 assignees hold 143 of 341 records in scope, so freedom-to-operate work should start with their claim sets, not a broad novelty search.
- Filings peaked in 2020 at 24. Volume fell from 22 in 2021 to 1 in 2024, a -95% swing over that span — read this against the 18-month publication lag rather than as proof the field is cooling.
- C12N carries 84.8% of records. Almost every filing touches microorganism or genetic-engineering claims, but A61K medicinal-preparation claims still reach 46.0% — export and uptake work is being claimed therapeutically, not just microbiologically.
341
Published Records
42%
Top-5 Share of All Records
-95%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (22 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 341 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview
What this landscape covers
Bacterial chassis transporter engineering covers patent claims on engineered or recombinant bacterial hosts where the invention turns on substrate uptake, product export, membrane permeability, efflux pump function, transporter specificity or uptake kinetics. This scope sits at the intersection of synthetic biology host engineering (C12N15/09), microorganism and culture-medium work (C12N1/20) and nucleic-acid measurement (C12Q1/68), which is where transporter modification claims are typically drafted and examined.
The 341 records in scope span 2015 through the 2026-07-31 cut-off. Because publication lags filing by roughly 18 months, the most recent one to two years understate true filing activity and should not be read as a decline.
Filing activity and technology mix, 2015 to present
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Bacterial Chassis Transporter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data
Filing trend and technology composition
Two views of the same 341 records: the year-by-year filing count, and the IPC subclasses those filings carry.
Filing trend, 2017-2026
Filings ran from 22 in 2017 to a peak of 24 in 2020, then declined to 1 by 2024 (-95% from the 2021 level of 22); 2025-2026 figures are still incomplete under the publication lag and should not yet be read as a trend reversal or confirmation.
IPC subclass composition
C12N (microorganisms and genetic engineering) appears in 84.8% of the 341 records, with A61K (medicinal preparations) at 46.0%, C12Q (enzyme/DNA measurement) and C07K (peptides and proteins) each near 28%, and C12P (fermentation and enzymatic synthesis) also at 27.9%. Because records can carry multiple classes, these shares sum to well over 100% and should be read individually, not combined.
Shares are the percentage of the 341 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Bacterial Chassis Transporter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Bacterial Chassis Transporter Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about bacterial chassis transporter engineering and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Representative and most-cited filings
Representative record
US5989832A — Method for screening for non-tetracycline efflux pump inhibitors
REMPEX PHARMACEUTICALS, INC.
Methods are provided for screening for inhibitors of microbial efflux pumps including those which export antibiotics. The screening methods are based on the increase in the intracellular concentration of a compound, such as an antibiotic, when the bacterial cells are contacted with an efflux pump inhibitor. In addition, this invention provides pharmaceutical compositions containing such efflux pump inhibitors, and methods for treating microbial infections using those compositions.Filed by Rempex Pharmaceuticals; granted 1999-11-23.
Most-cited records in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5223409A | Directed evolution of novel binding proteins | 14,049 |
| 2 | US20070172839A1 | Asymmetrical adapters and methods of use thereof | 279 |
| 3 | US7033781B1 | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and o… | 120 |
| 4 | WO2015159068A1 | therapeutic | 99 |
| 5 | US5989832A | Method for screening for non-tetracycline efflux pump inhibitors | 92 |
| 6 | US20170196225A1 | Altering microbial populations & modifying microbiota | 79 |
| 7 | US20180371405A1 | Methods and compositions for delivery of crispr based antimicrobials | 69 |
| 8 | US20180146681A1 | Altering microbial populations & modifying microbiota | 68 |
| 9 | US20180064114A1 | Altering microbial populations & modifying microbiota | 68 |
| 10 | US20180084785A1 | Altering microbial populations & modifying microbiota | 68 |
Citation counts reflect influence within the searched corpus and favour older filings; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Bacterial Chassis Transporter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing decision
Three findings that change where a team should search, file or license.
Concentration
62.8%
of 341 records held by 10 assignees
The field is concentrated, but not closed
Ten assignees account for 214 of the 341 records in scope, with the leader alone holding 62. That leaves close to two-fifths of the corpus spread across a long tail of single- or few-filing entrants, which is where freedom-to-operate risk is more diffuse and harder to map by name alone.
Assignee ranking, 100 companies
Momentum
-95%
2021 (22 filings) to 2024 (1 filing)
Recent volume has thinned sharply
The drop from 22 filings in 2021 to 1 in 2024 is steep enough to be a genuine slowdown in new filing activity, not just a lag artefact, since 2024 is the last year treated as complete. It does not mean the underlying science stalled — it means fewer new claims were staked in this specific scope in that window.
Filing growth, 2021-2024
Claim shape
46.0%
of 341 records also carry A61K
Transporter claims are increasingly therapeutic
Nearly half of records pair the core C12N microorganism claim with an A61K medicinal-preparation claim, and 15.0% also carry A61P therapeutic-activity language. A transporter modification filed as a delivery or dosing mechanism competes in a different claim space than one filed purely as a fermentation or production tool.
IPC composition, 341 records
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bacterial chassis transporter engineering, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Bacterial Chassis Transporter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who holds the ground, and where it is open
The leader board is short; the co-filing pattern behind it is shorter still.
Leader
62
records
One assignee sets the pace
The top-ranked assignee holds 62 of the 341 records, more than three times the fifth-place count of 20. That gap is wide enough that a competitive read of this space has to start with the leader's claim scope specifically, not just the aggregate top-5 figure.
Assignee ranking
Co-filing cluster
20
shared records, three pairings
A tight academic-industry cluster co-files repeatedly
Three assignee pairs each share 20 co-filed records, all drawn from the same small group of a sequencing-technology firm and two university-affiliated biotech institutes. That pattern points to a joint research programme rather than incidental overlap, and licensing conversations in this pocket likely involve all three parties.
Co-assignee pairs, 10 total
Momentum check
0
latest-year filings across leading assignees
Even the leaders show no recent-year output
Every assignee tracked for recent-year momentum, including the field leader and the tightly co-filing cluster, shows zero filings in the latest year and a -100% year-on-year reading where prior-year activity existed. Given the 18-month publication lag, this reads as an incomplete data window rather than an abandoned programme.
Recent-year momentum by assignee
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| SNIPR Biome (SNIPR Tech) | 0 | -100% |
| Nemesis Bioscience | 0 | — |
| Oxford Nanopore Technologies Ltd | 0 | -100% |
| Vrije Universiteit Brussel | 0 | -100% |
| Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) | 0 | -100% |
| The University of Iowa Research Foundation | 0 | — |
| The Regents of the University of California | 0 | — |
| LanzaTech NZ Inc | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Bacterial Chassis Transporter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this next
The dataset points to specific next steps rather than a general watch list.
Map the leader's claim boundaries
With 62 of 341 records, the top assignee's granted claims are the first place to check before drafting new uptake or export claims in this scope.
Explore assignee claims in EurekaWatch the co-filing cluster
The sequencing-and-university cluster behind the three 20-record co-filing pairs is worth tracking for licensing terms and joint continuation filings.
Track this cluster in EurekaRe-run the trend after the lag window closes
2024 is the last complete filing year in this corpus; a re-check once 2025-2026 publications catch up will confirm whether the -95% drop is a real slowdown.
Set a landscape alert in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Bacterial Chassis Transporter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on this landscape
One assignee leads with 62 of the 341 records in scope, well ahead of the fifth-ranked filer at 20. The top 5 assignees together hold 143 records, or 41.9% of the field, and the top 10 hold 214 records, or 62.8%. That leaves a long tail of smaller filers holding the remaining share, so a full competitive picture requires looking past just the largest names.
Filings peaked in 2020 at 24 and fell to 1 by 2024, a -95% drop from the 2021 level of 22. Because publication lags filing by around 18 months, 2025 and 2026 figures are still incomplete and should not be treated as confirmation of a continued decline. Based on the last complete year, 2024, filing activity in this exact claim scope has thinned substantially from its 2020-2021 peak.
C12N, covering microorganisms and genetic engineering, appears in 84.8% of the 341 records, making it the dominant classification by a wide margin. A61K medicinal preparations follow at 46.0%, with C12Q measurement methods, C07K peptides and proteins, and C12P fermentation each near 28%. Because a single record can carry several IPC classes, these percentages do not sum to 100% and should be read as independent shares of the same 341-record base.
US5989832A, assigned to Rempex Pharmaceuticals and granted in 1999, claims methods for screening compounds that inhibit microbial efflux pumps, based on measuring increased intracellular concentration of a test compound such as an antibiotic when combined with a candidate inhibitor. It also claims pharmaceutical compositions containing identified inhibitors and methods of treating microbial infections with them. Anyone building a new efflux-pump-inhibitor screening assay or a related pharmaceutical composition should review this claim set specifically, since it is one of the more highly cited records in this corpus and predates most of the filings in scope.
The composition data shows real filing activity but no single dominant claim holder in areas like transporter specificity engineering for non-native substrates, uptake kinetics measurement methods, and biocide-resistant export systems that overlap A01N agrochemical claims. These sit adjacent to the heavily claimed C12N and A61K core rather than inside it. A first claim in one of these branches would need to specifically differentiate the transporter mechanism or measurement method from the screening and composition claims already established by the most-cited prior art.
Answers are grounded in the same dataset. Derived from a Patsnap search on Bacterial Chassis Transporter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Bacterial Chassis Transporter Engineering in depth with Eureka
Go past this page: query the whole bacterial chassis transporter engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.